References
- Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on erwinia asparaginase. Cancer. 2011;117(2):238–249.
- Raetz EA, Salzer WL. Tolerability and efficacy of L-Asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32(7):554–563.
- MacDonald T, Kulkarni K, Bernstein M, et al. Allergic reactions with intravenous compared with intramuscular pegaspargase in children with high-risk acute lymphoblastic leukemia: a population-based study from the maritimes, Canada. J Pediatr Hematol Oncol. 2016;38(5):341–344.
- Salzer WL, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood. 2013;122(4):507–514.
- Kloos RQH, van Litsenburg RRL, Wolf S, et al. A cost-effectiveness analysis of erwinia asparaginase therapy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019;66(1):e27458–7.
- Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol. 2020;38(17):1897–1905.
- Rau RE, Dreyer Z, Choi MR, et al. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated erwinia asparaginase, pegcrisantaspase: a report from the children's oncology group. Pediatr Blood Cancer. 2018;65(3):e26873–14.
- Common Terminology Criteria for Adverse Events (CTCAE) v5 published November 27, 2027 U.S Department of Health and Human Services https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
- Cox LS, Sanchez-Borges M, Lockey RF. World allergy organization systemic allergic reaction grading system: is a modification needed? J Allergy Clin Immunol Pract. 2017;5(1):58–62.
- Verma A, Chen K, Bender C, et al. PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability. Pediatr Hematol Oncol. 2019;36(5):277–286.
- Swanson HD, Panetta JC, Barker PJ, et al. Predicting success of desensitization after pegaspargase allergy. Blood. 2020;135(1):71–75.
- Pike M, MacDonald T, Kulkarni K. Asparaginase activity monitoring and management of asparaginase hypersensitivity reactions in Canada. J Oncol Pharm Pract. 2021:1–7. 107815522110554. doi:10.22541/au.161419331.13710686/v1 (online ahead of print)
- Pike M, Kulkarni K, MacDonald T. Asparaginase activity monitoring experience from the Maritimes, Canada. Leuk Lymphoma. 2019;60(9):2312–2315.
- Brigitha LJ, Pieters R, van der Sluis IM. How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review. Eur J Cancer. 2021;157:238–249.
- Marini BL, Brown J, Benitez L, et al. A single-center multidisciplinary approach to managing the global erwinia asparaginase shortage. Leuk Lymphoma. 2019;60(12):2854–2868.